Literature DB >> 10613995

Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.

S M Jafri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10613995     DOI： 10.1023/a:1018766829995

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  11 in total

1.  Evidence for a heparin-induced conformational change on antithrombin III.

Authors:  G B Villaneuva; I Danishefsky
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

2.  Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G Söderström
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

3.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Authors:  W Klein; A Buchwald; S E Hillis; S Monrad; G Sanz; A G Turpie; J van der Meer; E Olaisson; S Undeland; K Ludwig
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

4.  Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

Authors:  M Sobel; P M McNeill; P L Carlson; J C Kermode; B Adelman; R Conroy; D Marques
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.

Authors:  R Collins; S MacMahon; M Flather; C Baigent; L Remvig; S Mortensen; P Appleby; J Godwin; S Yusuf; R Peto
Journal:  BMJ       Date:  1996-09-14

6.  Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa.

Authors:  F A Ofosu; J Hirsh; C T Esmon; G J Modi; L M Smith; N Anvari; M R Buchanan; J W Fenton; M A Blajchman
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

7.  ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

8.  Heparin binding to plasma proteins, an important mechanism for heparin resistance.

Authors:  E Young; M Prins; M N Levine; J Hirsh
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  Pharmacology of low molecular weight heparins.

Authors:  J Harenberg
Journal:  Semin Thromb Hemost       Date:  1990-10       Impact factor: 4.180
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.